[Protective effects of urinastatin on organ function in patients with severe burn].
OBJECTIVE
To investigate the protective effects of urinastatin on organ function in severe burn.


METHODS
Seventy-two cases with comparative severity in burn injury were randomly divided into urinastatin treatment group (n=36) and control group (n=36). Patients in control group received routine therapy, while those in treatment group received intravenous dripping of urinastatin twice a day for 5 to 7 days. The dosage of urinastatin was 300 kU in severe burns and 200 kU in moderate burns. Both polyvinylpyrrolidone iodine (PVP-I) and Jiedu Shaoshang cream were used for wound dressing. The clinical findings were assessed and variables indicating functions of internal organs, including liver (alanine aminotransferase), kidney (blood urea nitrogen, serum creatinine), heart (aspartate aminotransferase, lactate dehydrogenase, alpha-hydroxybutyrate dehydrogenase, creatine kinase, isoenzymes of creatinine kinase), and coagulation (prothrombin time, international normalized ratio, activated partial thromboplastin time, fibrinogen), as well as blood routine test, troponin, myoglobin, arterial blood analysis, bacteria culture were measured.


RESULTS
In treatment group, vital signs and general condition were satisfactory at shock phase and peri-operative stages in all the patients. Edema of burn wound subsided rapidly. The 28-day mortality rate was 0. There was significant difference between the two groups (all P<0.05).


CONCLUSIONS
Urinastatin has protective effects on multiple organs in severe burn injury.
Xu
Ying-bin
YB
Department of Burn, The First Affiliated Hospital, Sun Yat Sen University, Guangzhou 510080, Guangdong, China.
Qi
Shao-hai
SH
Xie
Ju-lin
JL
Yuan
Ji-shan
JS
Zhang
Tao
T
Chen
Xiao-dong
XD
Shu
Bin
B
Liu
Po
P
Li
Tian-zeng
TZ
D000293:Adolescent; D000328:Adult; D002056:Burns / Q000188:drug therapy / Q000503:physiopathology*; D005260:Female; D006023:Glycoproteins / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009102:Multiple Organ Failure / Q000517:prevention & control; D014361:Trypsin Inhibitors / Q000627:therapeutic use*; D055986:Vital Signs; D055815:Young Adult
D006023:Glycoproteins; D014361:Trypsin Inhibitors; C028665:urinastatin